Utrecht’s Laigo Bio Secures €17 Million to Propel Cancer and Autoimmune Therapies

In a significant development for the biotech landscape, Utrecht-based Laigo Bio has successfully closed its Seed funding round, amassing a total of €17 million. This financial milestone underscores the growing confidence in the company's innovative approach to treating cancer and autoimmune diseases. With an additional €5.5 million secured in the second closing, Laigo Bio is poised to accelerate its groundbreaking therapeutic programs.

Introduction

Laigo Bio, at the forefront of biotech innovation, has developed a proprietary platform known as SureTACs (Surface Removal Targeting Chimeras). This technology leverages bispecific antibody molecules to precisely degrade membrane proteins that play pivotal roles in disease progression. By targeting these "undruggable" proteins, SureTACs offers a novel therapeutic pathway, potentially redefining treatment paradigms for conditions such as cancer and autoimmune disorders.

Main Body

The latest funding infusion includes €4 million from new co-lead investor Biovance Capital and €1.5 million from existing co-lead Kurma Partners. This financial backing is not just a vote of confidence but a strategic alignment, as Biovance Capital's General Partner, Dr. João Incio, joins Laigo's board of directors, bringing valuable expertise to guide the company's future.

Laigo Bio's journey began with the support of the Oncode Institute, Oncode Bridge Fund, and Argobio Studio—a French biotech incubator launched by Kurma Partners, BPI France, and Angelini Ventures. Argobio Studio, with its €50 million capital commitment, focuses on creating biotech spinouts in specialized therapeutic areas, further validating Laigo Bio's strategic vision.

Insights / Analysis

Laigo Bio's approach to drug discovery exemplifies the innovative spirit that startups must embody to disrupt traditional industries. By addressing previously intractable targets, the company not only positions itself at the cutting edge of biotech innovation but also offers invaluable lessons for other startups. The collaboration with academic institutions like UMC Utrecht and the Oncode Institute highlights the importance of synergy between academia and industry in translating research breakthroughs into viable therapies.

For investors, Laigo Bio's success story reinforces the potential of investing in early-stage biotech firms with disruptive technologies. The involvement of a diverse syndicate of international investors—including Curie Capital, Eurazeo, and Cancer Research Horizons—demonstrates the global interest in pioneering therapeutic platforms.

Conclusion

Laigo Bio's €17 million Seed round closure is a pivotal moment in its journey to transform cancer and autoimmune disease treatment. With its SureTACs platform, the company is not only pushing the boundaries of what's possible in biotech but also setting a precedent for innovation-driven startups. As Laigo Bio advances its oncology programs and autoimmune candidate therapies towards clinical realization, it stands as a beacon of potential for the biotech industry and an inspiration for startups worldwide.

Source: EU-Startups